A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
{{output}}
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) were first introduced for the treatment of type 2 diabetes (T2D) in 2005. Despite the high efficacy and other benefits of GLP-1RAs, their uptake was initially limited by the fact that they could only... ...
